Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors

Basic Research in Cardiology, Journal Year: 2024, Volume and Issue: unknown

Published: July 17, 2024

Abstract Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by unleashing the power of immune system against malignant cells. However, their use is associated with a spectrum adverse effects, including cardiovascular complications, which can pose significant clinical challenges. Several mechanisms contribute to toxicity ICIs. First, dysregulation checkpoints, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein-1 (PD-1) its ligand (PD-L1), molecular mimicry cardiac autoantigens, leads immune-related events, myocarditis vasculitis. These events result from aberrant activation T cells self-antigens within myocardium or vascular endothelium. Second, disruption homeostasis ICIs lead autoimmune-mediated inflammation tissues, manifesting dysfunction heart failure, arrhythmias, pericarditis. Furthermore, upregulation inflammatory cytokines, particularly tumor necrosis factor-alpha, interferon-γ, interleukin-1β, interleukin-6, interleukin-17 contributes endothelial dysfunction, plaque destabilization, thrombosis, exacerbating risk on long term. Understanding intricate side effects induced crucial for optimizing patient care ensure safe effective integration immunotherapy into broader range treatment protocols. The implications these underscore importance vigilant monitoring early detection in patients receiving Future key pathological mediators biomarkers may aid prompt diagnosis cardiotoxicity will allow timely interventions.

Language: Английский

Nanoengineered immune check point inhibitors delivery for targeted brain cancer treatment: Current status and future perspectives

Biochemical Pharmacology, Journal Year: 2025, Volume and Issue: 233, P. 116789 - 116789

Published: Feb. 1, 2025

Language: Английский

Enhanced antitumor efficacy of bispecific antibody blocking PD-L1 and LAG-3 with doxorubicin: mechanism and safety evaluation

Breast Cancer Research and Treatment, Journal Year: 2025, Volume and Issue: unknown

Published: March 6, 2025

Language: Английский